Hyperferritinémie associée au syndrome métabolique: une nouvelle cible thérapeutique [Dysmetabolic hyperferritinemia: a new target for treatment?].

Details

Ressource 1Request a copy Under indefinite embargo.
UNIL restricted access
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_991CC70AC97E
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Hyperferritinémie associée au syndrome métabolique: une nouvelle cible thérapeutique [Dysmetabolic hyperferritinemia: a new target for treatment?].
Journal
Revue Médicale Suisse
Author(s)
Waeber G., Vollenweider P., Marques-Vidal P.M.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
2013
Volume
9
Number
404
Pages
2002-2007
Language
french
Notes
Publication types: English Abstract ; Journal Article Publication Status: ppublish
Abstract
Dysmetabolic hyperferritinemia is currently the most frequent cause of elevated ferritin levels in the general population. Whether dysmetabolic hyperferritinemia is a cause or an effect of insulin resistance is still a matter of debate. Still, several findings have been well established: increased iron intake or elevated ferritin levels are individual risk factors for diabetes, metabolic syndrome or gestational diabetes. When in presence of dysmetabolic hyperferritinemia, a small number of randomized controlled trials have suggested that therapeutic measures aimed at reducing ferritin levels such as low red meat consumption, deferoxamin or therapeutic phlebotomies have shown a beneficial effect on glucose homeostasis, lipid profile and impaired hepatic markers observed in non-alcoholic steatohepatitis.
Keywords
Biological Markers/metabolism, Fatty Liver/physiopathology, Fatty Liver/therapy, Ferritins/blood, Glucose/metabolism, Humans, Insulin Resistance, Lipids/blood, Metabolic Diseases/complications, Metabolic Diseases/physiopathology, Risk Factors
Pubmed
Create date
07/01/2014 15:53
Last modification date
13/01/2024 8:09
Usage data